Abbott Laboratories (ABT) 37.86 $ABT
Dane Bremer of Liberty Mutual Named New Chairperson of NETS
BusinessWire - Mon Jun 13, 8:30AM CDT
The Network of Employers for Traffic Safety (NETS) is pleased to announce the election of Dane Bremer, Director - Corporate Safety & Global Business Continuity for Liberty Mutual, as NETS Board Chairperson for 2016 and 2017. Bremer replaces Joe McKillips, Director, Commercial Program Support for Abbott Laboratories, following a successful two-year term. Liberty Mutual has been a NETS board member company since 1996, with Dane as the representative since 2013.
ABT: 37.86 (-0.54)
Watch for Abbott Laboratories to Potentially Rebound After Falling 1.38% Yesterday
Comtex SmarTrend(R) - Fri Jun 10, 1:08PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $38.23 to a high of $38.70. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $38.65 on volume of 4.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 37.86 (-0.54)
India Cardiovascular Devices Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Medtronic, St. Jude Medical, Abbott Labs - Research and Markets
BusinessWire - Fri Jun 10, 12:10PM CDT
Research and Markets has announced the addition of the "India Cardiovascular Devices Market Outlook to 2021 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others" report to their offering.
ABT: 37.86 (-0.54), MDT: 85.70 (unch), STJ: 76.82 (-0.53)
Abbott Declares 370th Consecutive Quarterly Dividend
PR Newswire - Fri Jun 10, 10:05AM CDT
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26 cents per share.
ABT: 37.86 (-0.54)
7 Medical Stocks to Buy with Market-Beating Yields
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:50AM CDT
Medical is one of the very few sectors that generally show great resilience during volatile phases in the market.
KND: 11.07 (-0.45), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43), HLS: 40.28 (-0.26), DRAD: 5.50 (+0.01)
World Food Intolerance Products Market Worth USD 13.9 Billion by 2022 - Analysis, Technologies & Forecasts Report 2016-2022 - Key Vendors: Abbott Labs, Danone, Kellogg - Research and Markets
BusinessWire - Thu Jun 09, 8:34AM CDT
Research and Markets has announced the addition of the "World Food Intolerance Products Market - Opportunities & Forecasts, 2015 - 2022" report to their offering.
ABT: 37.86 (-0.54)
Valeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 10:24AM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) were down 14.6% after the company slashed its guidance for 2016 due to continued weakness across most of its business franchises.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), VRX: 23.78 (-0.36), ARQL: 1.73 (-0.05)
Abbott Laboratories (ABT) Crosses Pivot Point Support at $38.81
Comtex SmarTrend(R) - Wed Jun 08, 9:09AM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $39.04 and have already reached the first level of support at $38.81. Should the shares continue to fall, the support pivots of $38.68 and $38.32 will be of interest.
ABT: 37.86 (-0.54)
Merrimack Announces Positive Data on Oncology Candidate
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 3:57PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) announced results from the phase I study on pipeline candidate, MM-151.
MACK: 6.27 (-0.05), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55)
Exelixis Up on Positive Kidney Cancer Data on Cabometyx
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 2:46PM CDT
Exelixis, Inc. (EXEL), along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), EXEL: 7.38 (unch)
ChromaDex Names Former Chairman & CEO of The Quaker Oats Company, William Smithburg, to its Board of Directors
GlobeNewswire - Tue Jun 07, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that William Smithburg has joined the Company's board of directors as an independent director.
ABT: 37.86 (-0.54), CDXC: 5.65 (+0.29)
Novartis (NVS) Announces Data on Leukemia Drug Tasigna
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:44PM CDT
Novartis AG (NVS) announced results from the Treatment-free Remission (TFR) program on oncology drug, Tasigna.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), NVS: 77.33 (-1.61)
Global Osteoarthritis Pain Market 2016-2020 - Preference for Alternative Therapies - Key Vendors are Pfizer, Novartis & Abbott Laboratories - Research and Markets
BusinessWire - Thu Jun 02, 11:16AM CDT
Research and Markets has announced the addition of the "Global Osteoarthritis Pain Market 2016-2020" report to their offering.
ABT: 37.86 (-0.54), NVS: 77.33 (-1.61)
Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:56AM CDT
Novo Nordisk (NVO) announced positive results on its pipeline candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), NVO: 54.72 (-0.64), SNY: 39.00 (-0.41)
Watch for Shares of Abbott Laboratories (ABT) to Approach Resistance at $39.69
Comtex SmarTrend(R) - Tue May 31, 9:24AM CDT
Shares of Abbott Laboratories (NYSE:ABT) have bullishly opened above the pivot of $39.21 today and have reached the first resistance level of $39.49. Investors may be interested in a cross of the next upside pivot targets of $39.69 and $40.17.
ABT: 37.86 (-0.54)
Abbott Laboratories (ABT) Breaks Through Resistance at $39.05
Comtex SmarTrend(R) - Fri May 27, 9:20AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $38.79 today and has reached the first level of resistance at $39.05. Analysts will be watching for a cross of the next upside pivot targets of $39.20 and $39.61.
ABT: 37.86 (-0.54)
BRIC Interventional Cardiology Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Abbott Labs, Medtronic, St. Jude Medical - Research and Markets
BusinessWire - Fri May 27, 6:25AM CDT
Research and Markets has announced the addition of the "BRIC Interventional Cardiology Market Outlook to 2021" report to their offering.
ABT: 37.86 (-0.54), MDT: 85.70 (unch), STJ: 76.82 (-0.53)
China Blood Testing (Typing, Immunoassay, NAT Testing) Market Report 2016 with Profiles of Abbott Laboratories, Bio-Rad Laboratories, DiaSorin & Grifols
GlobeNewswire - Fri May 27, 5:46AM CDT
Research and Markets has announced the addition of the "Blood Testing Market in China (Typing, Immunoassay, NAT Testing)" report to their offering.
ABT: 37.86 (-0.54)
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:59PM CDT
Seattle Genetics, Inc. (SGEN) announced that it has initiated a phase III trial, CASCADE, on vadastuximab talirine (SGN-CD33A).
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), SGEN: 39.31 (-1.07), SNY: 39.00 (-0.41)
Dr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:57PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) announced that it acquired a portfolio of OTC brands in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), RDY: 45.65 (+0.55)
Dane Bremer of Liberty Mutual Named New Chairperson of NETS
BusinessWire - Mon Jun 13, 8:30AM CDT
The Network of Employers for Traffic Safety (NETS) is pleased to announce the election of Dane Bremer, Director - Corporate Safety & Global Business Continuity for Liberty Mutual, as NETS Board Chairperson for 2016 and 2017. Bremer replaces Joe McKillips, Director, Commercial Program Support for Abbott Laboratories, following a successful two-year term. Liberty Mutual has been a NETS board member company since 1996, with Dane as the representative since 2013.
ABT: 37.86 (-0.54)
Watch for Abbott Laboratories to Potentially Rebound After Falling 1.38% Yesterday
Comtex SmarTrend(R) - Fri Jun 10, 1:08PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $38.23 to a high of $38.70. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $38.65 on volume of 4.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 37.86 (-0.54)
India Cardiovascular Devices Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Medtronic, St. Jude Medical, Abbott Labs - Research and Markets
BusinessWire - Fri Jun 10, 12:10PM CDT
Research and Markets has announced the addition of the "India Cardiovascular Devices Market Outlook to 2021 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others" report to their offering.
ABT: 37.86 (-0.54), MDT: 85.70 (unch), STJ: 76.82 (-0.53)
Abbott Declares 370th Consecutive Quarterly Dividend
PR Newswire - Fri Jun 10, 10:05AM CDT
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26 cents per share.
ABT: 37.86 (-0.54)
7 Medical Stocks to Buy with Market-Beating Yields
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:50AM CDT
Medical is one of the very few sectors that generally show great resilience during volatile phases in the market.
KND: 11.07 (-0.45), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43), HLS: 40.28 (-0.26), DRAD: 5.50 (+0.01)
World Food Intolerance Products Market Worth USD 13.9 Billion by 2022 - Analysis, Technologies & Forecasts Report 2016-2022 - Key Vendors: Abbott Labs, Danone, Kellogg - Research and Markets
BusinessWire - Thu Jun 09, 8:34AM CDT
Research and Markets has announced the addition of the "World Food Intolerance Products Market - Opportunities & Forecasts, 2015 - 2022" report to their offering.
ABT: 37.86 (-0.54)
Valeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 10:24AM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) were down 14.6% after the company slashed its guidance for 2016 due to continued weakness across most of its business franchises.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), VRX: 23.78 (-0.36), ARQL: 1.73 (-0.05)
Abbott Laboratories (ABT) Crosses Pivot Point Support at $38.81
Comtex SmarTrend(R) - Wed Jun 08, 9:09AM CDT
Shares of Abbott Laboratories (NYSE:ABT) opened today below their pivot of $39.04 and have already reached the first level of support at $38.81. Should the shares continue to fall, the support pivots of $38.68 and $38.32 will be of interest.
ABT: 37.86 (-0.54)
Merrimack Announces Positive Data on Oncology Candidate
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 3:57PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) announced results from the phase I study on pipeline candidate, MM-151.
MACK: 6.27 (-0.05), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55)
Exelixis Up on Positive Kidney Cancer Data on Cabometyx
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 2:46PM CDT
Exelixis, Inc. (EXEL), along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), EXEL: 7.38 (unch)
ChromaDex Names Former Chairman & CEO of The Quaker Oats Company, William Smithburg, to its Board of Directors
GlobeNewswire - Tue Jun 07, 5:30AM CDT
ChromaDex Corp. (NASDAQ:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients, that creates science-based solutions to dietary supplement, food and beverage, skin care, sports nutrition, and pharmaceutical products, announced today that William Smithburg has joined the Company's board of directors as an independent director.
ABT: 37.86 (-0.54), CDXC: 5.65 (+0.29)
Novartis (NVS) Announces Data on Leukemia Drug Tasigna
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:44PM CDT
Novartis AG (NVS) announced results from the Treatment-free Remission (TFR) program on oncology drug, Tasigna.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), NVS: 77.33 (-1.61)
Global Osteoarthritis Pain Market 2016-2020 - Preference for Alternative Therapies - Key Vendors are Pfizer, Novartis & Abbott Laboratories - Research and Markets
BusinessWire - Thu Jun 02, 11:16AM CDT
Research and Markets has announced the addition of the "Global Osteoarthritis Pain Market 2016-2020" report to their offering.
ABT: 37.86 (-0.54), NVS: 77.33 (-1.61)
Novo Nordisk (NVO) Reports Positive Data on Diabetes Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 8:56AM CDT
Novo Nordisk (NVO) announced positive results on its pipeline candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), NVO: 54.72 (-0.64), SNY: 39.00 (-0.41)
Watch for Shares of Abbott Laboratories (ABT) to Approach Resistance at $39.69
Comtex SmarTrend(R) - Tue May 31, 9:24AM CDT
Shares of Abbott Laboratories (NYSE:ABT) have bullishly opened above the pivot of $39.21 today and have reached the first resistance level of $39.49. Investors may be interested in a cross of the next upside pivot targets of $39.69 and $40.17.
ABT: 37.86 (-0.54)
Abbott Laboratories (ABT) Breaks Through Resistance at $39.05
Comtex SmarTrend(R) - Fri May 27, 9:20AM CDT
Abbott Laboratories (NYSE:ABT) has opened bullishly above the pivot of $38.79 today and has reached the first level of resistance at $39.05. Analysts will be watching for a cross of the next upside pivot targets of $39.20 and $39.61.
ABT: 37.86 (-0.54)
BRIC Interventional Cardiology Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Abbott Labs, Medtronic, St. Jude Medical - Research and Markets
BusinessWire - Fri May 27, 6:25AM CDT
Research and Markets has announced the addition of the "BRIC Interventional Cardiology Market Outlook to 2021" report to their offering.
ABT: 37.86 (-0.54), MDT: 85.70 (unch), STJ: 76.82 (-0.53)
China Blood Testing (Typing, Immunoassay, NAT Testing) Market Report 2016 with Profiles of Abbott Laboratories, Bio-Rad Laboratories, DiaSorin & Grifols
GlobeNewswire - Fri May 27, 5:46AM CDT
Research and Markets has announced the addition of the "Blood Testing Market in China (Typing, Immunoassay, NAT Testing)" report to their offering.
ABT: 37.86 (-0.54)
Seattle Genetics Starts Trial on Acute Myeloid Leukemia Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:59PM CDT
Seattle Genetics, Inc. (SGEN) announced that it has initiated a phase III trial, CASCADE, on vadastuximab talirine (SGN-CD33A).
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), SGEN: 39.31 (-1.07), SNY: 39.00 (-0.41)
Dr. Reddy's (RDY) Acquires Ducere Pharma's OTC Brands
Zacks Equity Research - Zacks Investment Research - Thu May 26, 2:57PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) announced that it acquired a portfolio of OTC brands in the cough-and-cold, pain, and dermatology categories from Ducere Pharma.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), RDY: 45.65 (+0.55)
